1 / 6

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program

The Health Strategies Consultancy. The Intersection of Business Strategy and Public Policy. Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program. John Richardson National Medicare Prescription Drug Congress February 27, 2004.

jess
Download Presentation

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Health Strategies Consultancy The Intersection of Business Strategy and Public Policy Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program John Richardson National Medicare Prescription Drug Congress February 27, 2004

  2. What is a Prescription Drug Discount Card? • Commercial products that lower retail price of Rx drugs • Target market: Consumers who have no or limited insurance coverage for prescription drugs • Individual generally must sign up to enroll, may pay enrollment fee • Sponsors: Membership organizations (e.g., AARP, AAA); pharmacy benefit managers (PBMs); retail pharmacies; health plans; states; pharmaceutical manufacturers • Operations: Sponsor or subcontracted PBM will— • Negotiate with other entities in supply chain that affect retail price • Provide IT infrastructure to deliver negotiated discounts at point of sale when enrollee presents their card

  3. How Do Card Sponsors Secure Retail Price Discounts? • Card Sponsor (or PBM subcontractor) • Negotiate rebates and/or discounts with pharmacies and manufacturers (if applicable) • Pass portion of rebates and discounts through to card holders; retain portion to cover own costs and profit • Retail Pharmacies • Negotiate with card sponsor/PBM for inclusion in card’s pharmacy network and level of dispensing fees and mark-up • Pharmaceutical Manufacturers • Negotiate rebates with card sponsors for “preferred drug” status (if applicable, i.e., there is some form of drug list)

  4. Price Offered by Card Programs is Influenced by a Number of Factors Regional Variation Pharmacy Type (retail, mail order, Internet) Generic vs. Brand Drug Price Negotiating Power of Card Sponsor

  5. Dec. 8, 2003: MMA is signed into law Dec. 15: CMS publishes interim final rule for discount card program Dec. 18-19: CMS holds pre-application conference for potential card sponsors and other interested parties Jan. 14, 2004: Deadline for public comment on interim final rule Jan. 30: Deadline for card sponsor applications to CMS End of March: Card sponsor contracts finalized April 1: Card sponsor information and outreach may begin April 30: CMS launches Discount Card Price Comparison Web site May 3: Card sponsors may begin enrollment June 1: Discount card program begins Nov. 15 - Dec. 31: Enrollees may elect to switch cards for 2005 Jan. 1, 2006: Part D benefit starts; discount card program ends Key Dates in Implementation of Medicare Drug Discount Card Program

  6. Concluding Thoughts and Questions • Nature of drug price disclosures—how well will beneficiaries understand and process drug pricing information? • Will CMS-mandated “therapeutic categories” produce manufacturer rebates and thus added value for beneficiaries? • Discount card program is “first date” between CMS and pharma industry—What expectations will be set? • Strong interest from potential card sponsors & drug manufacturers • Opportunity in marketing of card and establishing brand visibility • CMS balancing regulatory oversight and incredibly fast “go-live” imperative, while also learning about very complex industry • Both partners building relationship needed for success of Part D

More Related